Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyJ. Clin. Oncol 2021 Apr 12;[EPub Ahead of Print], AS Alva, PK Mangat, E Garrett-Mayer, S Halabi, D Hansra, CJ Calfa, MF Khalil, ER Ahn, TL Cannon, P Crilley, JG Fisher, DS Haslem, S Shrestha, KR Antonelli, NL Butler, SL Warren, AL Rygiel, S Ranasinghe, SS Bruinooge, RL Schilsky
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.